» Articles » PMID: 21441457

Type I IFNs Control Antigen Retention and Survival of CD8α(+) Dendritic Cells After Uptake of Tumor Apoptotic Cells Leading to Cross-priming

Overview
Journal J Immunol
Date 2011 Mar 29
PMID 21441457
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Cross-presentation is a crucial mechanism for generating CD8 T cell responses against exogenous Ags, such as dead cell-derived Ag, and is mainly fulfilled by CD8α(+) dendritic cells (DC). Apoptotic cell death occurring in steady-state conditions is largely tolerogenic, thus hampering the onset of effector CD8 T cell responses. Type I IFNs (IFN-I) have been shown to promote cross-priming of CD8 T cells against soluble or viral Ags, partly through stimulation of DC. By using UV-irradiated OVA-expressing mouse EG7 thymoma cells, we show that IFN-I promote intracellular Ag persistence in CD8α(+) DC that have engulfed apoptotic EG7 cells, regulating intracellular pH, thus enhancing cross-presentation of apoptotic EG7-derived OVA Ag by CD8α(+) DC. Notably, IFN-I also sustain the survival of Ag-bearing CD8α(+) DC by selective upmodulation of antiapoptotic genes and stimulate the activation of cross-presenting DC. The ensemble of these effects results in the induction of CD8 T cell effector response in vitro and in vivo. Overall, our data indicate that IFN-I cross-prime CD8 T cells against apoptotic cell-derived Ag both by licensing DC and by enhancing cross-presentation.

Citing Articles

The cGAS/STING Pathway-A New Potential Biotherapeutic Target for Gastric Cancer?.

Tian M, Zhang S, Tan F J Pers Med. 2024; 14(7).

PMID: 39063990 PMC: 11277918. DOI: 10.3390/jpm14070736.


The Toxoplasma Effector GRA4 Hijacks Host TBK1 to Oppositely Regulate Anti-T. Gondii Immunity and Tumor Immunotherapy.

Hu Z, Zhang Y, Xie Y, Yang J, Tang H, Fan B Adv Sci (Weinh). 2024; 11(32):e2400952.

PMID: 39031880 PMC: 11348266. DOI: 10.1002/advs.202400952.


Agonists and Inhibitors of the cGAS-STING Pathway.

Yu X, Cai L, Yao J, Li C, Wang X Molecules. 2024; 29(13).

PMID: 38999073 PMC: 11243509. DOI: 10.3390/molecules29133121.


Signaling by Type I Interferons in Immune Cells: Disease Consequences.

Zannikou M, Fish E, Platanias L Cancers (Basel). 2024; 16(8).

PMID: 38672681 PMC: 11049350. DOI: 10.3390/cancers16081600.


Potential roles for efferocytosis in glioblastoma immune evasion.

Lorimer I Neurooncol Adv. 2024; 6(1):vdae012.

PMID: 38616895 PMC: 11012614. DOI: 10.1093/noajnl/vdae012.